Avtor/Urednik		Zver, Samo
Naslov		Določitev števila aktiviranih trombocitov s protitelesi za aktivirani fibrinogen in selektin-P pri bolnikih z esencialno trombocitemijo in vpliv antiagregacijskih zdravil
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Medicinska fakulteta
Leto izdaje		2003
Obseg		str. 43
Jezik		slo
Abstrakt		Background: Essential thrombocythemia (ET) is a chronic myeloproliferative disease with a platelet count within the range of 400-2000x109/L. Higher percentage of platelets in the circulation of patients with ET, express also activation markers on their membranes. Two of such markers are P-selectin and activated fibrinogen on platelet membranes. Because of frequent thrombembolic and also bleeding related complications, treatment of ET is mandatory. Patients, whose platelet count is less than 1000 x 1091L and who did not suffer any thrombembolic complication during the course of the disease, we ussually treat with an antiaggregation drug, acetylsalicylic acid 100 mg/daily orally. During the last years, especially in the field of cardiology, clopidogrel, a new antiaggregational agent have been used. Clopidogrel is an adenosyn-di-phosphate (ADP) receptor antagonist in platelets. There is no routine clinical data about clopidogrel treatment in the patients with ET and only sporadic case reports can be find in the literature. Goal: In our clinical study we compared antiaggregational effects of acetylsalicylic acid and clopidogrel, by measuring the level of P-selectin and activated fibrinogen expression on platelet membranes. Our working hypotesis stated, that antiaggregational effect of clopidogrel is comparable to the antiaggregational effect of acetylsalicylic acid. Patients and methods: In the clinical study 3 5 ET patients were included, within the age range between 21 and 78 years and with platelet counts within 451-952 x 109/L. None of the patients did not suffer any thrombembolic complication during the course of the disease. During the sequential fourteen days periods, patients received acetylsalicylic acid 100 mg/daily orally, followed by clopidogrel 75 mg/daily orally and ultimativelly, together acetylsalicylic acid 100 mg/daily orally plus clopidogrel 75 mg/daily orally. (Abstract truncated at 2000 characters).
Deskriptorji		THROMBOCYTHEMIA, HEMORRHAGIC PLATELET AGGREGATION INHIBITORS FIBRINOGEN SELECTINS PLATELET ACTIVATION PLATELET COUNT FLOW CYTOMETRY ASPIRIN RECEPTORS, PURINERGIC P2 PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX ANTIBODIES, MONOCLONAL